Skip to main content

Table 1 Characteristics of the studies included

From: Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis

#TitleAuthorYearCountryLanguageStudy designAge# centersMedian follow-upSample sizeStageTreatmentBreast cancer subtype–IHCPD-L1Outcomes/end points
              Clone+-%       
1                        
2                        
3                        
4                        
  1. Breast cancer subtypes–immunohistochemistry: luminal A, luminal B, HER2-positive or triple-negative
  2. Outcomes: OS Overall survival: death from breast cancer, death from non-breast cancer cause and death from unknown cause, PFS progression-free survival
  3. BCSS BC-specific survival, DFS disease-free survival: invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, and second primary invasive cancer (non-breast), RFS recurrence-free survival: invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, and death from unknown cause, PLN positive lymph node, DM distant metastasis, DDFS distant disease-free survival: distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, and second primary invasive cancer (non-breast)
  4. Pathological response after neoadjuvant chemotherapy: Stage: I, II, III, IV. Treatment: surgery status, neoadjuvant chemotherapy status, adjuvant endocrine and chemotherapy status, and radiotherapy